Wall Street Zen Upgrades Gyre Therapeutics (NASDAQ:GYRE) to “Hold”

Gyre Therapeutics (NASDAQ:GYRE) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also issued reports on GYRE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Wednesday. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Gyre Therapeutics Price Performance

NASDAQ GYRE opened at $4.76 on Friday. The firm has a market cap of $530.79 million, a price-to-earnings ratio of -23.80 and a beta of 2.14. The business has a 50-day moving average price of $6.51 and a 200-day moving average price of $6.90. Gyre Therapeutics has a twelve month low of $3.97 and a twelve month high of $9.14.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.19. Gyre Therapeutics had a negative return on equity of 7.44% and a negative net margin of 14.80%. The company had revenue of $32.93 million for the quarter, compared to the consensus estimate of $28.40 million. Research analysts expect that Gyre Therapeutics will post -0.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $6,550,000. SBI Securities Co. Ltd. boosted its position in shares of Gyre Therapeutics by 1.8% during the 3rd quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock valued at $1,244,000 after acquiring an additional 2,967 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics during the 2nd quarter valued at approximately $414,000. Dimensional Fund Advisors LP grew its holdings in shares of Gyre Therapeutics by 131.8% in the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock valued at $176,000 after purchasing an additional 14,365 shares in the last quarter. Finally, Deutsche Bank AG purchased a new position in shares of Gyre Therapeutics in the second quarter valued at $118,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.